Phase 2Completed

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection

An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Sponsor
Rebiotix Inc. (Industry)
Enrollment
272 enrolled
Conditions
Clostridium Difficile Infection
Interventions
RBX2660; Standard of Care Antibiotics
Ages
adults, older adults
Registry
NCT02589847

Full record on ClinicalTrials.gov

From the registry

This study will evaluate efficacy and safety information about RBX2660 for the treatment of recurrent Clostridium difficile infection (CDI), and will compare the efficacy of one treatment with RBX2660 versus antibiotic-treated historical controls. Enrolled subjects will receive one treatment consisting of two doses of RBX2660 (microbiota suspension).

Primary outcomes

  • Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Registered

  6. Started